C4 Therapeutics (CCCC) Depreciation & Amortization (CF) (2019 - 2026)
C4 Therapeutics' quarterly Depreciation & Amortization (CF) came in at $404000.0 in Q1 2026, down 11.4% year-on-year from $456000.0 in Q1 2025, and down 5.61% quarter-over-quarter from $428000.0 in Q4 2025.
C4 Therapeutics has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $404000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 11.4% year-over-year to $404000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 4.44% YoY), and the FY2025 full-year result was $2.0 million, up 7.76% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $404000.0, down from $428000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $615000.0 in Q2 2025, with the low at $300000.0 in Q1 2022.
- Average Depreciation & Amortization (CF) over 5 years is $452176.5, with a median of $448000.0 recorded in 2024.
- Year-over-year, Depreciation & Amortization (CF) sank 33.48% in 2022 and jumped 66.67% in 2023.
- Tracing CCCC's Depreciation & Amortization (CF) over 5 years: stood at $521000.0 in 2022, then fell by 17.47% to $430000.0 in 2023, then advanced by 11.63% to $480000.0 in 2024, then decreased by 10.83% to $428000.0 in 2025, then slipped by 5.61% to $404000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $404000.0 (Q1 2026), $428000.0 (Q4 2025), and $460000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | 404,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 404,000.00 |
| Mar 31, 2026 | 404,000.00 |
| Dec 31, 2025 | 428,000.00 |
| Dec 31, 2025 | 428,000.00 |
| Sep 30, 2025 | 460,000.00 |
| Sep 30, 2025 | 460,000.00 |
| Jun 30, 2025 | 615,000.00 |
| Jun 30, 2025 | 615,000.00 |
| Mar 31, 2025 | 456,000.00 |
| Mar 31, 2025 | 456,000.00 |
| Dec 31, 2024 | 480,000.00 |
| Dec 31, 2024 | 480,000.00 |
| Sep 30, 2024 | 442,000.00 |
| Sep 30, 2024 | 442,000.00 |
| Jun 30, 2024 | 448,000.00 |
| Jun 30, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Dec 31, 2023 | 430,000.00 |
| Dec 31, 2023 | 430,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Jun 30, 2023 | 458,000.00 |
| Jun 30, 2023 | 458,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 521,000.00 |
| Dec 31, 2022 | 521,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Jun 30, 2022 | 435,000.00 |
| Jun 30, 2022 | 435,000.00 |
| Mar 31, 2022 | 300,000.00 |
| Mar 31, 2022 | 300,000.00 |
| Dec 31, 2021 | 323,000.00 |
| Dec 31, 2021 | 323,000.00 |
| Sep 30, 2021 | 330,000.00 |
| Sep 30, 2021 | 330,000.00 |
| Jun 30, 2021 | 388,000.00 |
| Jun 30, 2021 | 388,000.00 |
| Mar 31, 2021 | 451,000.00 |
| Mar 31, 2021 | 451,000.00 |
| Dec 31, 2020 | 365,000.00 |
| Dec 31, 2020 | 365,000.00 |
| Sep 30, 2020 | 420,000.00 |
| Sep 30, 2020 | 420,000.00 |
| Jun 30, 2020 | 416,000.00 |
| Jun 30, 2020 | 416,000.00 |
| Mar 31, 2020 | 416,000.00 |
| Mar 31, 2020 | 416,000.00 |
| Dec 31, 2019 | 422,000.00 |
| Dec 31, 2019 | 422,000.00 |